Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + S-1 in advanced gastric/GEJ cancer
NCT03276156Phase 1Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Progression Free Survival at 4 months and Incidence of adverse events at 4 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03276156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276156.